andBiobank consortium
Together for biomedical research on ME/CFS
Bridging Science between ME/CFS and other PAIS
Join our fight against ME/CFS
Together patients, scientists and clinicians can make a difference for ME/CFS. We have bundled our knowledge and expertise in the NMCB consortium. Together we will spearhead biomedical research on ME/CFS in the Netherlands. And more! Join our effort!
What is ME/CFS?
ME/CFS
ME/CFS is a serious disease that disrupts patients’ lives and causes a lot of suffering. ME/CFS patients experience continuous and intense exhaustion. Next to that symptoms can worsen even after minimal mental, physical, emotional or social effort – something that is called “post-exertionele malaise” (PEM).
ME/CVS-symptoms:
- Post-exertional malaise (PEM)
- Muscle pain, headache
- Poor quality of sleep
- Sensitive to stimuli
- Overall feeling of illness and exhaustion
- Cognitive problems
WHAT WILL NMCB DO?
Building an international ME/CFS hub
Biomedical research
Despite the impact of ME/CFS, much is still unknown about its causes and possible treatments. NMCB recognises the need for biomedical research on ME/CFS. By establishing a national patient cohort and biobank, we are building an international infrastructure for research to improve the knowledge, diagnosis and treatment of ME/CFS.
NMCB research
In an eight-year collaboration between scientific and clinical experts, as well as patients, the NMCB will enable in-depth research divided first of all into six subprojects. In collaboration with an international research network, the NMCB will establish an international ME/CFS hub to facilitate additional research on ME/CFS.
Collaborations
Patient representatives
Patients and their experiences are an essential part of the NMCB. In collaboration with three ME/CFS patient organisations, we want to ensure that patients’ experiences remain central to our studies.
Get in Touch
Contacts
Do you have any questions about the NMCB? Feel free to reach out using the form below, or find your question at the FAQ page.
















